Dupixent (dupilumab) has become the first biologic medicine for chronic obstructive pulmonary disease (COPD) in the US and China. Sanofi and Regeneron secured approvals from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) in the same week. It is approved for adults with uncontrolled chronic obstructive pulmonary disease […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!